Inventiva is a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis, or NASH, mucopolysaccharidoses, or MPS, and other diseases. Co. maintains a pipeline backed by a discovery engine with a library of proprietary molecules, a wholly-owned research and development facility and a team engaged in developing compounds that target nuclear receptors, transcription factors and epigenetic modulation. Co. is advancing two clinical candidates, lanifibranor and odiparcil for the treatment of NASH and MPS, respectively, as well as a pipeline of earlier stage programs in oncology and other diseases. The IVA stock yearly return is shown above.
The yearly return on the IVA stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2020 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the IVA annual return calculation with any dividends reinvested as applicable (on ex-dates).
|